BRPI0918539A2 - preparação farmacêutica sólida para administração oral - Google Patents

preparação farmacêutica sólida para administração oral

Info

Publication number
BRPI0918539A2
BRPI0918539A2 BRPI0918539A BRPI0918539A BRPI0918539A2 BR PI0918539 A2 BRPI0918539 A2 BR PI0918539A2 BR PI0918539 A BRPI0918539 A BR PI0918539A BR PI0918539 A BRPI0918539 A BR PI0918539A BR PI0918539 A2 BRPI0918539 A2 BR PI0918539A2
Authority
BR
Brazil
Prior art keywords
oral administration
pharmaceutical preparation
solid pharmaceutical
solid
preparation
Prior art date
Application number
BRPI0918539A
Other languages
English (en)
Inventor
Takeshi Matsushita
Yusuke Mochizuki
Original Assignee
Daiichi Sankyo Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42005183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0918539(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Healthcare Co filed Critical Daiichi Sankyo Healthcare Co
Publication of BRPI0918539A2 publication Critical patent/BRPI0918539A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
BRPI0918539A 2008-09-12 2009-09-09 preparação farmacêutica sólida para administração oral BRPI0918539A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008235354 2008-09-12
PCT/JP2009/065700 WO2010029930A1 (ja) 2008-09-12 2009-09-09 変色が抑制された安定な医薬製剤

Publications (1)

Publication Number Publication Date
BRPI0918539A2 true BRPI0918539A2 (pt) 2015-12-08

Family

ID=42005183

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918539A BRPI0918539A2 (pt) 2008-09-12 2009-09-09 preparação farmacêutica sólida para administração oral

Country Status (9)

Country Link
EP (1) EP2335697B1 (pt)
JP (1) JP5498387B2 (pt)
KR (1) KR101623608B1 (pt)
CN (1) CN102137663B (pt)
BR (1) BRPI0918539A2 (pt)
HK (1) HK1152651A1 (pt)
MX (1) MX340436B (pt)
TW (1) TWI445527B (pt)
WO (1) WO2010029930A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101670693B1 (ko) * 2009-10-20 2016-10-31 다이이찌 산쿄 헬스케어 가부시키가이샤 변색 및 냄새가 억제된 필름 코팅정
JP2013049671A (ja) * 2011-08-04 2013-03-14 Fancl Corp アスコルビン酸製剤
JP6245786B2 (ja) * 2011-10-17 2017-12-13 大同化成工業株式会社 医薬用結合剤及び該結合剤を用いた製剤
CN103054861A (zh) * 2012-12-29 2013-04-24 北京阜康仁生物制药科技有限公司 一种含氨甲环酸的复方固体制剂
US10028915B2 (en) 2014-07-25 2018-07-24 The Nippon Synthetic Chemical Industry Co., Ltd. Polyvinyl alcohol particles, pharmaceutical binder using same, pharmaceutical tablet, sustained-release pharmaceutical tablet, and method for producing polyvinyl alcohol particles
CA3060366A1 (en) * 2017-04-28 2018-11-01 Astellas Pharma Inc. Pharmaceutical composition for oral administration comprising enzalutamide
JP2019081757A (ja) * 2017-10-31 2019-05-30 武田コンシューマーヘルスケア株式会社 固形製剤の製造方法
EP3863598A1 (en) * 2018-10-09 2021-08-18 DSM IP Assets B.V. Topical composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04243825A (ja) * 1991-01-25 1992-08-31 Ss Pharmaceut Co Ltd 色素沈着症治療剤
JPH093348A (ja) * 1995-06-20 1997-01-07 Lion Corp 色素の変色抑制方法及び色素配合組成物
JP4596732B2 (ja) 2000-08-29 2010-12-15 日新化成株式会社 硬カプセル
JP2004217655A (ja) 2002-12-27 2004-08-05 Dai Ichi Seiyaku Co Ltd 美白用組成物
JP2004250376A (ja) * 2003-02-20 2004-09-09 Lion Corp 医薬組成物用色素、医薬組成物用色素の製造方法、医薬組成物及び医薬組成物の変色・退色防止方法
WO2005019286A1 (ja) * 2003-08-20 2005-03-03 Shionogi & Co., Ltd. 新規コーティング組成物
JP2005068115A (ja) * 2003-08-28 2005-03-17 Pola Chem Ind Inc 安定な皮膚外用剤
JP2005314403A (ja) 2004-03-31 2005-11-10 Dai Ichi Seiyaku Co Ltd 新規美白用組成物
JPWO2006003965A1 (ja) * 2004-06-30 2008-04-17 第一三共ヘルスケア株式会社 美白組成物
JP5614826B2 (ja) 2005-07-13 2014-10-29 塩野義製薬株式会社 退色を抑制した製剤
JP2007091670A (ja) 2005-09-29 2007-04-12 Shionogi & Co Ltd 退色が抑制された着色カプセル
JP2007197410A (ja) * 2006-01-30 2007-08-09 Lion Corp フィルムコーティング錠
JP2008201711A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd システイン臭が低減された固形製剤
MX2011001071A (es) * 2008-08-06 2011-04-26 Daiichi Sankyo Healthcare Co Composicion farmaceutica estable que contiene acido tranexamico y acido ascorbico.
BRPI0919194A2 (pt) * 2008-09-05 2015-12-15 Daiichi Sankyo Healthcare Co preparação sólida para administração oral

Also Published As

Publication number Publication date
MX2011002364A (es) 2011-04-04
HK1152651A1 (en) 2012-03-09
JPWO2010029930A1 (ja) 2012-02-02
EP2335697B1 (en) 2014-03-12
WO2010029930A1 (ja) 2010-03-18
KR101623608B1 (ko) 2016-05-23
CN102137663B (zh) 2016-09-28
EP2335697A4 (en) 2011-08-17
JP5498387B2 (ja) 2014-05-21
MX340436B (es) 2016-07-08
TW201016212A (en) 2010-05-01
CN102137663A (zh) 2011-07-27
EP2335697A1 (en) 2011-06-22
KR20110057151A (ko) 2011-05-31
TWI445527B (zh) 2014-07-21

Similar Documents

Publication Publication Date Title
DK2328601T3 (da) Linaclotid-holdige formuleringer til oral indgivelse
BRPI0818680A2 (pt) composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica
BRPI1007484A2 (pt) composição farmacêutica para administração oral
BRPI0820381A2 (pt) Formulações farmacêuticas
HK1164059A1 (en) Compositions for drug administration
ZA201005015B (en) Solid pharmaceutical dosage form
IL206159A0 (en) Oral pharmaceutical dosage forms
EP2591773A4 (en) TEMPORARY RELEASED PHARMACEUTICAL COMPOSITION WITH DAPOXIN FOR ORAL ADMINISTRATION
BRPI1008598A2 (pt) composição farmacêutica para inalação
BRPI0719394A2 (pt) Preparação medicinal sólida
BRPI0918539A2 (pt) preparação farmacêutica sólida para administração oral
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
BRPI0812964A2 (pt) Forma de dosagem farmacêutica oral sólida
EP2263637A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
BRPI0922653A2 (pt) preparação farmacêutica
EP2206519A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
BR112013014940A2 (pt) composições farmacêuticas de inibidores de fator xa seletivos para administração oral
BRPI0919194A2 (pt) preparação sólida para administração oral
BRPI0912656A2 (pt) formulação farmacêutica sólida
BRPI0922888A2 (pt) administração combinada de fármaco
BRPI0923379A2 (pt) Formulação para administração por via transmucosa oral de setronas
BRPI0919475A2 (pt) composição farmacêutica para administração oral
EP2253326A4 (en) PHARMACEUTICAL COMPOSITION FOR TRANSNASAL ADMINISTRATION
EP2520300A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
HUP0900482A2 (en) Pharmaceutical formulation for oral administration

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2373 DE 28-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.